P16 gene alterations in human ovarian cancers: Comparison between tissue and blood samples

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 553-560

  Bammidi, Lakshmi Sowjanya ^a   Neerukonda, Geetha Nagasree ^b   Murthy, Sudha ^b   Kanapuram, Rudrama Devi ^a  

^a OSMANIA UNIVERSITY   (India)

^b Indo American Cancer Institute and Research Centre   (India)

Author keywords

Mutation; Ovarian cancer; P16 Expression; P16 Gene; Promoter methylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; MONOCLONAL ANTIBODY; PROTEIN P16; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA METHYLATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84863644939     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823fa90c     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 1998. CA Cancer J Clin. 2005;55:74-108.
2. Nandakumar A. Biennial Report (1990-96) of National Cancer Registry Programme, Indian Council of Medical Research. New Delhi, India: National Printing Press; 2001.
3. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
4. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197-1206.
5. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
6. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-756.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
8. Cobrinik D, Dowdy SF, Hinds PW, et al. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci. 1992;17:312-315.
9. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
10. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell. 1999;97:53-61.
11. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42-55.
12. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237:7-13.
13. Campbell IG, Foulkes WD, Beynon G, et al. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995;63:222-225.
14. Schuyer M, van Staveren IL, Klijn JG, et al. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. Br J Cancer. 1996;74:1069-1073.
15. Marchini S, Codegoni AM, Bonazzi C, et al. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer. 1997;76:146-149.
16. Wong YF, Chung TK, Cheung TH, et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol Oncol. 1997;65:319-324.
17. Niederacher D, Yan HY, An HX, et al. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer. 1999;80:1920-1926.
18. Suh SI, Cho JW, Baek WK, et al. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett. 2000;153:175-182.
19. Fujita M, Enomoto T, Haba T, et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 1997;74:148-155.
20. Kanuma T, Nishida J, Gima T, et al. Alterations of the p16INK4A gene in human ovarian cancers. Mol Carcinog. 1997;18:134-141.
21. Shih YC, Kerr J, Liu J, et al. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer. 1997;70:508-511.
22. Zhang Y, Chao Y, Yang Z. Mutation and expression of p16 in human ovarian neoplasms. Hunan Yi Ke Da Xue Xue Bao. 1999;24:529-532.
23. Brown I, Milner BJ, Rooney PH, et al. Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncol Rep. 2001;8:1359-1362.
24. Milde-Langosch K, Ocon E, Becker G, et al. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 1998;79:61-65.
25. McCluskey LL, Chen C, Delgadillo E, et al. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol. 1999;72:87-92.